cumulative ulcer healing rate
Figure 2 · Panel Figure_2
Panel Figure_2 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Xiao Di, Changwei Liu, Siqiao Sun, Jinbao Qin, Xueli Guo, Yikuan Chen, Xin Li, Hongkun Zhang, Ming Liu, Liu Yang, Hui Zhao, Shaoying Lu, Jingyong Huang, Yunfeng Zhang, Jun Li, Xiaolei Lin, Kai Yao, Jingdong Tang, Jian Wang, Zhanfeng Gao, Jinjun Wang, Xiaojin Huang, Songshan Xu, Yue Liu, Wei Han, Leng Ni, Wei Ye, Yuehong Zheng, Yuexin Chen, Bao Liu
Mol Ther 33(7) 3423-3433
Intramuscular injection of donaperminogene seltoplasmid (recombinant human hepatocyte growth factor plasmids) represents a gene therapy that treats patients with chronic limb-threatening ischemia (CLTI). The HOPE CLTI-2 trial was a phase 3, multicenter, double-blind, placebo-controlled study aimed to evaluate the efficacy and safety of seltoplasmid in patients with Rutherford class 5 CLTI. This study did not require participants to be ineligible for revascularization, allowing enrollment of patients with CLTI caused by either atherosclerosis (ASO) or Buerger disease (or thromboangiitis obliterans [TAO]). The primary endpoint was the complete ulcer healing rate at 6 months. A total of 242 participants (53.3% ASO versus 46.7% TAO) were enrolled, with 161 receiving seltoplasmid and 81 receiving placebo. Complete ulcer healing was achieved in 70 patients in the seltoplasmid group compared to 15 patients in the placebo group, resulting in an adjusted healing rate difference of 26.1% (95% confidence interval [CI]: 15.1%-37.0%; p < 0.001). The hazard ratio for healing was 2.31 (95% CI: 1.32-4.05; p = 0.004). The benefits of seltoplasmid on ulcer healing persisted in both TAO and ASO subgroups. Serious adverse events were rare. Our study demonstrated that seltoplasmid significantly improved ulcer healing rates in patients with Rutherford class 5 CLTI compared to placebo.
2 个 Figure · 2 个 KM 面板
Figure 2 Kaplan-Meier curve of complete ulcer healing rate (full analysis set) Kaplan-Meier analyses for complete ulcer healing rate was performed using a time-dependent Cox regression analysis model to generate a hazard ratio adjusted for baseline ulcer size and comorbid diabetes. The p value was calculated against a two-sided alpha level of 0.05.
Figure 2 · Panel Figure_2
Panel Figure_2 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 Kaplan-Meier curve of amputation-free survival (full analysis set) Kaplan-Meier analyses for amputation-free survival was performed using a time-dependent Cox regression analysis model to generate a hazard ratio adjusted for baseline ulcer size and comorbid diabetes. The p value was calculated against a two-sided alpha level of 0.05.
Figure 3 · Panel amputation-free_survival
Panel amputation-free_survival 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。